Fungemia due to Kodamaea ohmeri in a young infant and review of the literature

Vivas, Rosalba; Beltrán, Claudia Milena Ospina; Múnera, María Isabel; Trujillo, Mónica; Restrepo, Alberto; Garcés, Carlos

doi:10.1016/j.mmcr.2016.06.001

Cited by 22 publications

(24 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, MIC 50 values and MIC ranges generated from data collected during an exhaustive 12-year surveillance program in France (8) were very similar to those reported for the same species in the current report (Table 5). Moreover, a number of anecdotal case reports support our evidence for elevated MICs or fluconazole resistance in many of the species listed in Table 2, including Yarrowia (Candida) lipolytica (7,8), Pichia cactophila and Pichia norvegensis (7,8,(26)(27)(28)(29), C. blankii (30), Candida palmioleophila (7,31), Candida zeylanoides (29,32,33), Diutina (Candida) catenulata (7,34), Pichia fermentans (29), Pichia mandshurica (8), Debaryomyces hansenii (Candida famata) (29,35,36), Kodamaea ohmeri (8,35,(37)(38)(39), Trichosporon spp. (39)(40)(41), Rhodotorula spp.…”

Section: Discussionsupporting

confidence: 70%

Fluconazole Resistance in Isolates of Uncommon Pathogenic Yeast Species from the United Kingdom

Borman

Müller

Walsh-Quantick

et al. 2019

Antimicrob Agents Chemother

View full text Add to dashboard Cite

The triazole drug fluconazole remains one of the most commonly prescribed antifungal drugs, both for prophylaxis in high-risk patients and also as a second-line treatment option for invasive Candida infections. Established susceptibility profiles and clinical interpretive breakpoints are available for fluconazole with Candida albicans, Candida glabrata, Candida tropicalis, and Candida parapsilosis, which account for the majority of infections due to pathogenic yeast species. However, less common species for which only limited susceptibility data are available are increasingly reported in high-risk patients and from breakthrough infections. The UK National Mycology Reference Laboratory performs routine antifungal susceptibility testing of clinical isolates of pathogenic yeast submitted from across the United Kingdom. Between 2002 and 2016, ϳ32,000 isolates were referred, encompassing 94 different yeast species. Here, we present fluconazole antifungal susceptibility data generated using a CLSI methodology over this 15-year period for 82 species (2,004 isolates) of less common yeast and yeast-like fungi, and amphotericin B, fluconazole, itraconazole, voriconazole, posaconazole, and anidulafungin, with members of the Nakaseomyces clade (C. glabrata, Candida nivariensis, and Candida bracarensis). At least 22 different teleomorph genera, comprising 45 species, exhibited high MICs when tested with fluconazole (Ͼ20% of isolates with MICs higher than the clinical breakpoint [Ն8 mg/liter] proposed for C. albicans). Since several of these species have been reported anecdotally from breakthrough infections and therapeutic failures in patients receiving fluconazole, the current study underscores the importance of rapid and accurate yeast identification and may aid clinicians dealing with infections with rarer yeasts to decide whether fluconazole would be appropriate.

show abstract

Section: Discussionsupporting

confidence: 70%

Fluconazole Resistance in Isolates of Uncommon Pathogenic Yeast Species from the United Kingdom

Borman

Müller

Walsh-Quantick

et al. 2019

Antimicrob Agents Chemother

View full text Add to dashboard Cite

show abstract

“…No additional studies were found during the hand‐screening of the included articles' references. Finally, 35 met the present study's inclusion criteria 3,4,7–39 . The review process is graphically presented in Figure 1.…”

Section: Resultsmentioning

confidence: 99%

“…Among the 35 studies on K ohmeri infections, 30 (85.7%) reported fungemias, accounting for 36 patients out of 44 (81.8%) in total 3,4,7–34 . A concomitant infection was present in 22.2% (8 out of 36 fungemias), namely infective endocarditis (IE) in 11.1% (4 cases), 31–34 skin and soft tissue infection (SSTI) in 5.6% (2 cases), 16,21 disseminated infection with involvement of the spleen, urinary tract and lower respiratory tract in 2.8% (1 case), 8 and lower respiratory tract infection in 2.8% (1 case) 29 .…”

Section: Resultsmentioning

confidence: 99%

Kodamaea ohmeri infections in humans: A systematic review

Ιωάννου

Papakitsou

2020

Mycoses

View full text Add to dashboard Cite

Summary Background Kodamaea ohmeri, previously known as Pichia ohmeri or Yamadazyma ohmeri, belongs to the Saccharomycetaceae family and the Ascomycetae class, is the telomorphic form of C guilliermondii var. membranaefaciens and is frequently mistaken for Candida, as they belong to the same family. It has been isolated from environmental sources, such as sand, pools, seawater and fruits, while the last decades it is recognised as a rare pathogen that causes life‐threatening infections in humans. The purpose of this study was to systemically review all published cases of K ohmeri infections in the literature and describe the epidemiology, microbiology, antimicrobial susceptibility, treatment and outcomes of these infections in humans. Methods Systematic review of PubMed (through 27th December 2019) for studies providing epidemiological, clinical, microbiological as well as treatment data and outcomes of K ohmeri infections. Results A total of 35 studies, containing data of 44 patients, were included in the analysis. The most common K ohmeri infections were those of the bloodstream, infective endocarditis and onychomycosis. Previous antibiotic use, presence of a central venous catheter, parenteral nutrition and cancer were very common among patients. Mortality was high in the case of fungemias but low for other types of infections. Amphotericin B and fluconazole are the most common agents used for treatment, even though alarming MICs for fluconazole were noted. Conclusions This systematic review thoroughly describes infections by K ohmeri and provides information on their epidemiology, clinical presentation, microbiology, antibiotic resistance patterns, treatment and outcomes.

show abstract

“…There have been 88 reports of infection with K. ohmeri described in the literature. Among them, 76 patients presented with fungaemia and the remaining presented with peritonitis (three patients), endocarditis (four patients), urinary tract infection (one patient), polymicrobial wound infection (one patient) and oral ulcer (three patients). In the present case, the lesion was exclusively limited to the site of the wound without systemic involvement.…”

Section: Discussionmentioning

confidence: 99%

Subcutaneous granuloma caused by Kodamaea ohmeri in an immunocompromised patient in China

Yan

Gao

et al. 2019

Aust J Dermatology

View full text Add to dashboard Cite

We present a case of subcutaneous granuloma caused by Kodamaea ohmeri and describe the histopathological characteristics and skin lesions caused by this pathogen. A 55-year-old woman, with a history of rheumatoid arthritis, presented with red, painless plaque on her forehead, persistent for 3 months; based on the histopathological and mycological findings and gene sequencing, the patient was diagnosed with subcutaneous granuloma caused by K. ohmeri. This report highlights that early identification and diagnosis and optimal regimens are vital in the management of this intractable infection.

show abstract

Fungemia due to Kodamaea ohmeri in a young infant and review of the literature

Cited by 22 publications

References 17 publications

Fluconazole Resistance in Isolates of Uncommon Pathogenic Yeast Species from the United Kingdom

Fluconazole Resistance in Isolates of Uncommon Pathogenic Yeast Species from the United Kingdom

Kodamaea ohmeri infections in humans: A systematic review

Subcutaneous granuloma caused by Kodamaea ohmeri in an immunocompromised patient in China

Contact Info

Product

Resources

About